<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37247177</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">0975-0711</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology</Title><ISOAbbreviation>Indian J Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Fecal microbiota transplant delivered via invasive routes in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials.</ArticleTitle><Pagination><StartPage>315</StartPage><EndPage>323</EndPage><MedlinePgn>315-323</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12664-023-01373-5</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIMS">Irritable bowel syndrome (IBS) results in significant loss of quality of life. Management guidelines do not recommend fecal microbiota transplant (FMT) for IBS based on weak evidence as refined data is lacking. We performed a systematic review and meta-analysis to ascertain the pooled clinical outcomes of FMT in IBS, delivered via invasive routes.</AbstractText><AbstractText Label="METHODS">Multiple databases were searched through January 2023 to identify studies that reported on FMT treatment in IBS by invasive routes. Standard meta-analysis methodology using the random-effects model was used. Heterogeneity was assessed by I<sup>2</sup>% and 95% predication interval.</AbstractText><AbstractText Label="RESULTS">Five studies were included. As many as 377&#xa0;IBS patients were assessed, of which 238 received FMT and 139 received placebo. One study used nasojejunal tubes, one esophagogastroduodenoscopy&#xa0;and three colonoscopy for FMT delivery. FMT via colonoscopy was performed as a one-time procedure instilled into the cecum. Two studies used 30 g of stool from a single universal donor and one study used 50-80 g of pooled donor feces. The pooled odds ratio of improvement in IBS symptoms with FMT was significantly better as compared to that of placebo OR = 2.9 (95% CI [1.6-5.2, I<sup>2</sup> = 62%, p &lt; 0.001]). This was true for studies that exclusively used colonoscopy (OR = 2.1 [1.1-4.2, p = 0.04]). In the FMT arm, 10 patients (10.6%) reported abdomen pain and worsening of symptoms with bloating and six patients (6.3%) reported diarrhea.</AbstractText><AbstractText Label="CONCLUSION">FMT delivered via invasive routes, especially colonoscopy, demonstrated significant improvement in IBS symptoms. A single FMT consisting of 30 g or more of single universal donor feces instilled into the cecum is the predominant modality.</AbstractText><CopyrightInformation>&#xa9; 2023. Indian Society of Gastroenterology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Mohan</LastName><ForeName>Babu P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Gastroenterology and Hepatology, Veterans Affairs Medical Center and University of Utah Health School of Medicine, 30 N 1900 E SOM 4R118, Salt Lake City, UT, 84132, USA. dr.babu.pm@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Loganathan</LastName><ForeName>Priyadarshini</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Internal Medicine, UT Health, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Shahab R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garg</LastName><ForeName>Gauri</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Gastroenterology and Hepatology, Veterans Affairs Medical Center and University of Utah Health School of Medicine, 30 N 1900 E SOM 4R118, Salt Lake City, UT, 84132, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muthusamy</LastName><ForeName>Arunkumar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Gastroenterology and Hepatology, MNGI Digestive Health, Minnesota, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ponnada</LastName><ForeName>Suresh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Internal Medicine, Carilion Roanoke Medical Center, Roanoke, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasam</LastName><ForeName>Ravi Teja</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Internal Medicine, Wentworth Hospital, Dover, NH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandan</LastName><ForeName>Saurabh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Gastroenterology and Hepatology, CHI Creighton School of Medicine, Omaha, NE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuteja</LastName><ForeName>Ashok</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Gastroenterology and Hepatology, Veterans Affairs Medical Center and University of Utah Health School of Medicine, 30 N 1900 E SOM 4R118, Salt Lake City, UT, 84132, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Gastroenterol</MedlineTA><NlmUniqueID>8409436</NlmUniqueID><ISSNLinking>0254-8860</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069467" MajorTopicYN="N">Fecal Microbiota Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bloating</Keyword><Keyword MajorTopicYN="N">Colonoscopy</Keyword><Keyword MajorTopicYN="N">Constipation</Keyword><Keyword MajorTopicYN="N">Diarrhea</Keyword><Keyword MajorTopicYN="N">FMT</Keyword><Keyword MajorTopicYN="N">IBS</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">ROME criteria</Keyword></KeywordList><CoiStatement>BPM, PL, SRK, GG, AM, SP, RTP, SC and AT declare no competing interests.&#xfeff;</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>29</Day><Hour>13</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>29</Day><Hour>11</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37247177</ArticleId><ArticleId IdType="pmc">PMC10225764</ArticleId><ArticleId IdType="doi">10.1007/s12664-023-01373-5</ArticleId><ArticleId IdType="pii">10.1007/s12664-023-01373-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, et al. ACG clinical guideline: management of irritable bowel syndrome. Official J Ame College Gastroenterol ACG. 2021;116(1):17&#x2013;44. doi: 10.14309/ajg.0000000000001036.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001036</ArticleId><ArticleId IdType="pubmed">33315591</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman DA, Hasler WL. Rome IV&#x2014;functional GI disorders: disorders of gut-brain interaction. Gastroenterol. 2016;150(6):1257&#x2013;61. doi: 10.1053/j.gastro.2016.03.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.03.035</ArticleId><ArticleId IdType="pubmed">27147121</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712&#x2013;21. e4. doi: 10.1016/j.cgh.2012.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2012.02.029</ArticleId><ArticleId IdType="pubmed">22426087</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016;1(2):133&#x2013;46. doi: 10.1016/S2468-1253(16)30023-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(16)30023-1</ArticleId><ArticleId IdType="pubmed">28404070</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM, et al. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut. 2010;59(5):605&#x2013;11. doi: 10.1136/gut.2009.202234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2009.202234</ArticleId><ArticleId IdType="pubmed">20427395</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M, Hatlebakk JG, Gilja OH, Br&#xe5;thenKristoffersen A, Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020;69(5):859&#x2013;67. doi: 10.1136/gutjnl-2019-319630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2019-319630</ArticleId><ArticleId IdType="pmc">PMC7229896</ArticleId><ArticleId IdType="pubmed">31852769</ArticleId></ArticleIdList></Reference><Reference><Citation>Holster S, Lindqvist CM, Repsilber D, et al. The effect of allogenic versus autologous fecal microbiota transfer on symptoms, visceral perception and fecal and mucosal microbiota in irritable bowel syndrome: A randomized controlled study. Clin Transl Gastroenterol. 2019;10:e00034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6602784</ArticleId><ArticleId IdType="pubmed">31009405</ArticleId></ArticleIdList></Reference><Reference><Citation>Holvoet T, Joossens M, V&#xe1;zquez-Castellanos JF, Christiaens E, Heyerick L, Boelens J, et al. Fecal microbiota transplantation reduces symptoms in some patients with irritable bowel syndrome with predominant abdominal bloating: short-and long-term results from a placebo-controlled randomized trial. Gastroenterology. 2021;160(1):145&#x2013;57.e8. doi: 10.1053/j.gastro.2020.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.07.013</ArticleId><ArticleId IdType="pubmed">32681922</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnsen PH, Hilp&#xfc;sch F, Cavanagh JP, Leikanger IS, Kolstad C, Valle PC, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. 2018;3(1):17&#x2013;24. doi: 10.1016/S2468-1253(17)30338-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(17)30338-2</ArticleId><ArticleId IdType="pubmed">29100842</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahtinen P, Jalanka J, Hartikainen A, Mattila E, Hillil&#xe4; M, Punkkinen J, et al. Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome. Alimentary Pharma Therapeut. 2020;51(12):1321&#x2013;31. doi: 10.1111/apt.15740.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15740</ArticleId><ArticleId IdType="pubmed">32343000</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama. 2000;283(15):2008&#x2013;12. doi: 10.1001/jama.283.15.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.283.15.2008</ArticleId><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. Bmj. 2020;2021:372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1&#x2013;12. doi: 10.1016/0197-2456(95)00134-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(95)00134-4</ArticleId><ArticleId IdType="pubmed">8721797</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotton PB, Eisen GM, Aabakken L, et al. A lexicon for endoscopic adverse events: report of an ASGE workshop.&#xa0;Gastrointest&#xa0;&#xa0;Endosc. 2010;71:446&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">20189503</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177&#x2013;88. doi: 10.1016/0197-2456(86)90046-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(86)90046-2</ArticleId><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG, Deeks JJ. Altman DG Measuring inconsistency in meta-analyses. BMJ: British Med J. 2003;327(7414):557. doi: 10.1136/bmj.327.7414.557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.327.7414.557</ArticleId><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohan BP, Adler DG. Heterogeneity in systematic review and meta-analysis: how to read between the numbers. Gastrointest Endosc. 2019;89(4):902&#x2013;3. doi: 10.1016/j.gie.2018.10.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gie.2018.10.036</ArticleId><ArticleId IdType="pubmed">30902218</ArticleId></ArticleIdList></Reference><Reference><Citation>Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">1672966</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianiro G, Eusebi LH, Black CJ, Gasbarrini A, Cammarota G, Ford AC. Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. Alimentary Pharmacol Therapeut. 2019;50(3):240&#x2013;8. doi: 10.1111/apt.15330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15330</ArticleId><ArticleId IdType="pubmed">31136009</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Lv L, Wang C. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Front Cell Infect Microbiol. 2022;12:827395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8919053</ArticleId><ArticleId IdType="pubmed">35295757</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao HJ, Zhang XJ, Zhang NN, et al. Fecal microbiota transplantation for patients with irritable bowel syndrome: a meta-analysis of randomized controlled trials. Front Nutr. 2022;9:890357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9202577</ArticleId><ArticleId IdType="pubmed">35719141</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilleri M. FMT in IBS: a call for caution. Gut. 2021;70:431.</Citation><ArticleIdList><ArticleId IdType="pubmed">32414814</ArticleId></ArticleIdList></Reference><Reference><Citation>Myneedu K, Deoker A, Schmulson MJ, Bashashati M. Fecal microbiota transplantation in irritable bowel syndrome: a systematic review and meta-analysis. United Eur Gastroenterol J. 2019;7(8):1033&#x2013;41. doi: 10.1177/2050640619866990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050640619866990</ArticleId><ArticleId IdType="pmc">PMC6794695</ArticleId><ArticleId IdType="pubmed">31662860</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D, Chen VL, Steiner CA, Berinstein JA, Eswaran S, Waljee AK, et al. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a systematic review and meta-analysis. American J Gastroenterol. 2019;114(7):1043. doi: 10.14309/ajg.0000000000000198.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000000198</ArticleId><ArticleId IdType="pmc">PMC7257434</ArticleId><ArticleId IdType="pubmed">30908299</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuthpongtorn C, Kantagowit P, Pittayanon R, et al. Fecal microbiota transplantation in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Frontiers Med. 2022;3:3273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9669599</ArticleId><ArticleId IdType="pubmed">36405622</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazemian N, Kao D, Pakpour S. Fecal microbiota transplantation during and post-COVID-19 pandemic. Int J Molecul Sci. 2021;22(6):3004. doi: 10.3390/ijms22063004.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22063004</ArticleId><ArticleId IdType="pmc">PMC7998826</ArticleId><ArticleId IdType="pubmed">33809421</ArticleId></ArticleIdList></Reference><Reference><Citation>DeFilipp Z, Bloom PP, Torres Soto M, Mansour MK, Sater MR, Huntley MH, et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. New England J Med. 2019;381(21):2043&#x2013;50. doi: 10.1056/NEJMoa1910437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1910437</ArticleId><ArticleId IdType="pubmed">31665575</ArticleId></ArticleIdList></Reference><Reference><Citation>Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. Available at:&#xa0;https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-regarding-investigational-new-drug-requirements-use-fecal-microbiota. Accessed&#xa0;29 Mar 2022.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>